share_log

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

Mangoceuticals | 4：持股變動聲明-高管 Cohen Jacob D.
美股SEC公告 ·  08/28 07:45
牛牛AI助理已提取核心訊息
Jacob D. Cohen, CEO of Mangoceuticals, completed a transaction involving the company's common stock on August 26, 2024. The action, classified as a bona fide gift, consisted of both acquiring and disposing of 800,000 shares at no cost. Following the transaction, Cohen's direct holdings in Mangoceuticals common stock amounted to 9,075,000 shares.
Jacob D. Cohen, CEO of Mangoceuticals, completed a transaction involving the company's common stock on August 26, 2024. The action, classified as a bona fide gift, consisted of both acquiring and disposing of 800,000 shares at no cost. Following the transaction, Cohen's direct holdings in Mangoceuticals common stock amounted to 9,075,000 shares.
曼果生物公司CEO Jacob D. Cohen於2024年8月26日完成了一筆涉及公司普通股的交易。此舉被歸類爲真正的禮物，包括無償獲取和處置80萬股。交易結束後，cohen在曼果生物公司的直接持股股數達到了907.5萬股。
曼果生物公司CEO Jacob D. Cohen於2024年8月26日完成了一筆涉及公司普通股的交易。此舉被歸類爲真正的禮物，包括無償獲取和處置80萬股。交易結束後，cohen在曼果生物公司的直接持股股數達到了907.5萬股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。